Position in NVS
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$23,351
-$1,547 QoQ
Shares Held
149
-8.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#1,489
of 1,603 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026MV CAPITAL MANAGEMENT, INC. holds $82,370,025 across 15 Drug Manufacturers - General names. NVS ranks #10 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
271,250 | $68,257,350 | |
| 2 | JNJ |
Johnson & Johnson
|
14,678 | $3,727,771 | |
| 3 | AMGN |
Amgen Inc
|
8,630 | $3,125,095 | |
| 4 | LLY |
ELI LILLY & Co
|
2,477 | $2,970,988 | |
| 5 | MRK |
Merck & Co., Inc.
|
22,792 | $2,928,772 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
7,582 | $957,909 | |
| 7 | PFE |
Pfizer Inc
|
10,065 | $242,365 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
1,153 | $66,435 |
All Filings in NVS
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23,351 | 149 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $24,898 | 163 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $12,132 | 88 | Shares | Sole | 2026-02-23 | |
| 2025-09-30 | $8,720 | 68 | Shares | Sole | 2026-02-23 | |
| 2025-06-30 | $8,228 | 68 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $14,269 | 128 | Shares | Sole | 2025-04-15 | |
| 2024-12-31 | $12,455 | 128 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $14,722 | 128 | Shares | Sole | 2024-11-04 | |
| 2024-06-30 | $6,387 | 60 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $5,803 | 60 | Shares | Sole | 2024-04-18 | |
| 2023-12-31 | $6,058 | 60 | Shares | Sole | 2024-01-29 | |
| 2023-09-30 | $6,111 | 60 | Shares | Sole | 2023-11-07 | |
| No filing history on record for this holder in this stock. | ||||||